Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Larson Financial Group LLC

Larson Financial Group LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,205 shares of the biopharmaceutical company’s stock after purchasing an additional 1,370 shares during the period. Larson Financial Group LLC’s holdings in Gilead Sciences were worth $850,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Swedbank AB raised its position in Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares in the last quarter. Verdence Capital Advisors LLC increased its stake in shares of Gilead Sciences by 13.9% during the third quarter. Verdence Capital Advisors LLC now owns 26,699 shares of the biopharmaceutical company’s stock worth $2,238,000 after buying an additional 3,261 shares during the period. Lindbrook Capital LLC raised its holdings in Gilead Sciences by 10.1% in the third quarter. Lindbrook Capital LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $351,000 after acquiring an additional 382 shares in the last quarter. Sigma Planning Corp lifted its stake in Gilead Sciences by 1.6% in the third quarter. Sigma Planning Corp now owns 44,594 shares of the biopharmaceutical company’s stock worth $3,739,000 after acquiring an additional 693 shares during the last quarter. Finally, Alan B Lancz & Associates Inc. grew its holdings in Gilead Sciences by 4.7% during the 3rd quarter. Alan B Lancz & Associates Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $930,000 after acquiring an additional 500 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $117.41 on Monday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $118.42. The firm has a market capitalization of $146.22 billion, a price-to-earnings ratio of 317.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The business’s 50 day simple moving average is $99.61 and its 200-day simple moving average is $91.62. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on GILD shares. Mizuho lifted their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. BMO Capital Markets lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Piper Sandler boosted their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Finally, DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $104.24.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 293,356 shares of company stock valued at $29,166,240. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.